Publicaciones en colaboración con investigadores/as de Hospital Juan Ramón Jiménez (13)

2023

  1. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 3

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

    Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2014

  1. Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT

    Revista Espanola de Quimioterapia, Vol. 27, Núm. 2, pp. 93-97

2013

  1. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of staphylococcus aureus bacteremia

    Clinical Infectious Diseases, Vol. 57, Núm. 9, pp. 1225-1233

2011

  1. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/Hepatitis C Virus-Coinfected Patients

    AIDS Patient Care and STDs, Vol. 25, Núm. 7, pp. 395-402

2010

  1. Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: A multicentre prospective study

    AIDS Research and Therapy, Vol. 7

2008

  1. Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932

2000

  1. Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in naive human immunodeficiency virus-infected patients from Andalucía (Spain)

    Medicina Clinica, Vol. 115, Núm. 11, pp. 423-425

1998

  1. Comparative study of bacteremias caused by Enterococcus spp. with and without High-level resistance to gentamicin

    Journal of Clinical Microbiology, Vol. 36, Núm. 2, pp. 520-525

1996

  1. Prospective evaluation of fever of unknown origin in patients infected with the human immunodeficiency virus

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 15, Núm. 9, pp. 705-711